Study guide
4.3 Reproductive Planning & Fertility Preservation
Advanced Oncology Certified Nurse Practitioner AOCNP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide
2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling
3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment
4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship
4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence
5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy
5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies
6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology
7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy
7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies
8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)
9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety
9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions
10 Chapter 10: Supportive Care - Symptom & Comorbidity Management
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management
11 Chapter 11: Oncologic Emergencies
11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH
12 Chapter 12: Psychosocial Issues
12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources
13 Chapter 13: Professional Practice & Roles of the APRN
13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education
4.3 Reproductive Planning & Fertility Preservation
Key Takeaways Explain This Topic AI
ASCO recommends that clinicians discuss the possibility of treatment-related infertility with every patient of reproductive age as early as possible, and refer promptly to a reproductive specialist for those who are interested or uncertain.
Alkylating agents, particularly cyclophosphamide, busulfan, and procarbazine, plus total body irradiation and direct gonadal radiation, carry the highest risk of permanent gonadal failure.
Oocyte or embryo cryopreservation is the established fertility preservation method for post-pubertal females and typically requires about 2 weeks of ovarian stimulation, which is why referral must precede the first dose.
Sperm cryopreservation is the established method for post-pubertal males, is fast and inexpensive, and should be completed before the first gonadotoxic dose.
Effective contraception is required during and after treatment for agents with teratogenic or genotoxic potential, and tamoxifen is teratogenic even though it can induce ovulation.
Last updated: August 2026
4.3 Reproductive Planning & Fertility Preservation
Blueprint focus: ONCC Domain I.B.5 — Reproductive planning. This item sits inside Assessment and Diagnosis for a reason: the conversation belongs at diagnosis, before the first dose, not somewhere in survivorship.
Why Timing Dominates Everything
Fertility preservation is the one supportive-care intervention that becomes permanently impossible if it is delayed. Ovarian stimulation for oocyte or embryo cryopreservation typically takes about two weeks ; sperm banking takes a day. If the first cycle of chemotherapy is given first, the window may close forever. ASCO guidance is explicit: discuss the risk of infertility with all patients of reproductive age as early as possible , and refer promptly to reproductive specialists for anyone interested or ambivalent.
Documentation matters. Record that the discussion occurred, what the patient decided, and the referral made or declined. Survivors consistently report that infertility was among the most distressing consequences of treatment and that they were not adequately warned.
Which Treatments Threaten Fertility
Gonadotoxicity depends on agent class, cumulative dose, radiation field and dose, and — for women — age, since ovarian reserve declines with age and older patients have less margin.
Risk level Female Male
High Cyclophosphamide at high cumulative dose, busulfan, melphalan, procarbazine, chlorambucil; total body irradiation; pelvic or whole-abdominal radiation; conditioning for HSCT The same alkylating agents; testicular or pelvic radiation; total body irradiation
Intermediate Cisplatin, carboplatin, doxorubicin-based regimens; moderate-dose alkylators Cisplatin-based regimens (for example BEP for testicular cancer)
Lower Methotrexate, fluorouracil, vincristine, bleomycin, dactinomycin Same agents
Uncertain, requires caution Targeted agents, immune checkpoint inhibitors, and CAR T-cell therapy — long-term reproductive data are limited, so counsel as if risk exists Same
Radiation is field-dependent. Cranial radiation can cause hypothalamic-pituitary dysfunction and hypogonadotropic hypogonadism even when the gonads are untouched. Ovarian transposition (oophoropexy) can move ovaries out of a planned pelvic field. Uterine radiation impairs the ability to carry a pregnancy even when ovarian function is preserved.
Options for Post-Pubertal Females
Option Description Notes
Oocyte cryopreservation Controlled ovarian stimulation, retrieval, and vitrification of unfertilized eggs Established, not experimental; requires no partner or donor sperm; roughly 2 weeks
Embryo cryopreservation Stimulation and retrieval followed by fertilization and freezing Established; requires partner or donor sperm and raises disposition questions if the relationship changes
Ovarian tissue cryopreservation Laparoscopic harvest of cortical tissue for later reimplantation No longer considered experimental; the only option for pre-pubertal girls and for patients who cannot delay treatment
Ovarian transposition Surgical relocation of ovaries outside the radiation field Used before pelvic radiation; does not protect against systemic chemotherapy
GnRH agonist ovarian suppression Monthly agonist during chemotherapy May reduce premature ovarian insufficiency, especially in breast cancer, but is not a substitute for cryopreservation and should not be offered as the sole strategy
Third-party reproduction Donor oocyte, donor embryo, gestational carrier, adoption Discuss when preservation is not feasible
For hormone-receptor-positive breast cancer, letrozole- or tamoxifen-modified stimulation protocols limit the estradiol surge, and random-start protocols allow initiation at any point in the menstrual cycle, which shortens delay.
Options for Post-Pubertal Males
Sperm cryopreservation is the standard, is inexpensive relative to female options, and should be completed before the first gonadotoxic dose . Multiple samples are preferable but a single sample is far better than none.
Testicular sperm extraction (TESE) is an option for patients who cannot produce an ejaculated sample, including adolescents and men with azoospermia.
Testicular tissue cryopreservation remains investigational and is the only avenue for pre-pubertal boys.
Gonadal shielding during radiation reduces scatter dose.
Hormonal suppression of spermatogenesis during chemotherapy has not been shown to preserve fertility and should not be offered as protection.
Contraception and Pregnancy During Treatment
Confirm pregnancy status before initiating therapy in anyone who can become pregnant.
Most antineoplastic agents are teratogenic or genotoxic. Effective non-hormonal or appropriately chosen contraception is required during treatment and for an agent-specific interval afterward — commonly several months, and longer for agents with long half-lives or for male partners of people who can become pregnant.
Tamoxifen is teratogenic and can simultaneously induce ovulation in premenopausal women, so patients must be counseled that they may become more fertile while taking a drug that must not be taken during pregnancy. Contraception is required during therapy and for about 2 months after stopping.
Lenalidomide, thalidomide, and pomalidomide require enrollment in a restricted risk evaluation and mitigation strategy program with mandatory pregnancy testing and dual contraception.
Breastfeeding is contraindicated during most systemic therapy.
Cancer Diagnosed During Pregnancy
Pregnancy does not automatically require termination, and most patients can be treated.
Surgery is generally safest in the second trimester.
Chemotherapy is contraindicated in the first trimester because of organogenesis, but many regimens — including anthracycline- and taxane-based breast cancer regimens — can be given in the second and third trimesters . Methotrexate is avoided throughout.
Radiation is generally deferred until after delivery, particularly for abdominal and pelvic fields.
Targeted agents and immune checkpoint inhibitors are avoided; trastuzumab causes oligohydramnios.
Stop chemotherapy roughly 3 weeks before anticipated delivery so that maternal and neonatal counts recover and delivery does not occur at nadir.
Care requires a coordinated team of oncology, maternal-fetal medicine, neonatology, and psychosocial support.
Survivorship Follow-Through
Fertility does not resolve at the end of treatment. Assess for premature ovarian insufficiency with FSH and estradiol, screen for hypogonadism in men with morning testosterone, address sexual health and vaginal or erectile dysfunction directly, and revisit reproductive goals at survivorship visits. A patient who declined preservation at diagnosis while overwhelmed may want the conversation again once treatment ends.